Summit Therapeutics Share Price (SUMM)

157.50 0.00 (0.00%) delayed: 8:36AM GMT
Bid price 155.00 Open price 157.50
Ask price 160.00 Prev close 157.50
High price 0.00 Spread 3.13%
Low price 0.00 Volume 0

Register now for FREE live Summit Therapeutics share prices, Summit Therapeutics stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Summit Therapeutics Level 2 Data, indepth research tools and investor commentary for Summit Therapeutics (SUMM) and other London Stock Exchange equities.

Summit Therapeutics Share Price Chart

Advanced Charts >>

Register now for FREE Summit Therapeutics share price charts

Summit Therapeutics Share Price Information

Name Summit Therapeutics Epic SUMM
Sector Pharmaceuticals & Biotechnology ISIN GB00BN40HZ01
Activites Summit Therapeutics plc (formerly Summit Corporation plc, formerly VASTox plc) is an international biopharmaceutical company focussed on the discovery and development of novel medicines to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit's goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Index n/a

Summit Therapeutics Key Numbers

Latest Share Price (p) 157.50 Net Gearing (%) -49.30
Market Capitalisation (£m) 97.36 Gross Gearing (%) 15.72
Shares in issue (m) 61.82 Debt Ratio 3.37
P/E Ratio -3.84 Debt-to-Equity Ratio 0.19
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.19
Dividend Yield (%) 0.00 Price to book value 3.25
Dividend cover (x) 0.00 ROCE (%) -92.13
Earning per share (p) -41.00 EPS Growth (%) -41.38
52 week high / low 260.00 / 82.50 DPS Growth (%) n/a

Summit Therapeutics Director Deals

Dec.Date Type Director Pos No. of Shares
30/07/2014 BUY Glyn Edwards CEO 30,000
26/07/2013 PLAC Glyn Edwards CEO 600,000
26/07/2013 PLAC Dr Frank Armstrong CH 50,000
26/07/2013 PLAC Barry Price NED 500,000
26/07/2013 PLAC Jim Mellon RES 20,000,000

More Summit Therapeutics Director Deals >>

Summit Therapeutics Company News

12:00 15/12/2016

Summit Therapeutics plc : 3rd Quarter Results

Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 AND OPERATIONAL PROGRESS Oxford, UK, 15 December 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and...

15:00 13/12/2016

Summit Therapeutics plc : Notice of Results

Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED 31 OCTOBER 2016 ON 15 DECEMBER 2016 Oxford, UK, 13 December 2016 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company...

12:00 16/11/2016

Summit Enrolls Patients in the US into PhaseOut...

Summit Therapeutics plc ("Summit" or "the Company") SUMMIT ENROLS PATIENTS IN THE UNITED STATES INTO PhaseOut DMD, A PHASE 2 CLINICAL TRIAL OF EZUTROMID IN PATIENTS WITH DMD Oxford, UK, 16 November 2016 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development...

More Summit Therapeutics Company News >>

Register now for FREE Summit Therapeutics company news

Summit Therapeutics Share Price Discussions

3 months ago

Summit Corporation PLC (SUMM) Summit is an Oxford, UK based drug discovery company developing novel drug candidates to treat areas of high unmet medical need. Our strategy has evolved to focus on the development of two high-value clinical-stage programmes that target the fatal genetic disease...

more than 1 year ago

Summer Bonanza is upon us.......... (SUMM)

OK folks it's mid March and spring is upon us. Time to start looking ahead, the mkts have had a bit of a setback, is this the healthy correction that's been spoken about for so long or is it a buying opportunity on the road to new highs? Who knows, not me for sure, if I did I'd tell ya'll after...

Register now for FREE Summit Therapeutics share price discussions